Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To evaluate the impact of serum AMH levels on stimulated IVF implantation and clinical pregnancy rates.
• Design: Retrospective study with multivariate analysis.
• Setting: Clinique ovo (Montreal University affiliated Center).
• Patient(s): Six hundred and thirty seven patients undergoing a stimulated IVF protocol were included. Only non-polycystic ovary patients at their first IVF attempt were considered for the analysis.
• Intervention(s): None.
• Main outcome measures(s): Implantation and ongoing pregnancy rates.
Cycle outcomes were analysed according to AMH percentiles based on the AMH normogram per patient’s age of our infertile population. Multivariate analyses were done to adjust for potential confounding factors such as age, total exogenous FSH dosage and number of eggs retrieved. Compared to the reference population, a significant lower mean implantation rate (0.26 vs 0.45) was observed in patients under 35 years of age with AMH < 1 ng/ml. Women with AMH < 25th percentile had less chances of having an embryo transferred, lower chances of having an ongoing pregnancy per started IVF cycle and a lower embryo freezing rate compared to the reference population.
Patients with AMH < 0.47 ng/ml should be advised before starting a stimulated IVF cycle of the poorer prognosis compared to our reference population independently of their age, total exogenous FSH dosage and number of eggs retrieved. Therefore, AMH could enable a more individualized number of embryo transfer policy based on oocyte quality.
- Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718. CrossRef
- Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of anti-Mullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2008;22:193–201.
- Verlinsky Y, Cieslak J, Ivakhnenko V. Prevention of age-related aneuploidies by polar body testing of oocytes. J Assist Reprod Genet. 1999;16(4):165–9. CrossRef
- Hamamah S, Fallet C. Gene expression profile of human cumulus cells: clinical applications for IVF. J Gynecol Obstet Biol Reprod. 2010;39:5–7. CrossRef
- Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45:685–98. CrossRef
- Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996;81:571–6.
- Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulose cells. J Clin Endocrinol Metab. 1999;84:3836–44.
- Van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause. 2004;11:601–6. CrossRef
- Ain T, Soules MR, Collins JA. Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril. 2004;82:180–5. CrossRef
- Weghofer A, Margreiter M, Fauster Y, Schaetz T, Brandstetter A, Boehm D, et al. Age-specific FSH levels as a tool for appropriate patient counseling in assisted reproduction. Hum Reprod. 2005;20:2448–52. CrossRef
- La Marca A, De Leo V, Giulini S, Orvieto R, Malmusi S, Giannella L, et al. Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig. 2005;12:545–8. CrossRef
- La Marca A, Volpe A. Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf). 2006;64:603–10. CrossRef
- La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30. CrossRef
- Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol. 2007;24:1–8.
- La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. ESHRE Special Interest Group for Reproductive Endocrinology–AMH Round Table. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod. 2009;24:2264–75. CrossRef
- Broekmans FJ, Visser JA, Laven JSE, Broer SL, Themmen APN, Fauser BC. Anti-Mullerian hormone and ovarian dysfunction. Trends Endocrinol Metab. 2008;19:340–7. CrossRef
- Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, et al. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril. 2009;92:1674–8. CrossRef
- Steer CV, Mills CL, Tan SL, Campbell S, Edwards RG. The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer program. Hum Reprod. 1992;7(1):117–9.
- Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26(6):1270–83. CrossRef
- Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation anti-Müllerian hormone (AMH) ELISA. J Immunol Methods. 2010;362(1–2):51–9. CrossRef
- Broer SL, Mol B, Dólleman M, Fauser BC, Broekmans FJ. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol. 2010;22(3):193–201. Review. CrossRef
- La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103–7. CrossRef
- Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012;27(3):631–6. CrossRef
- Catteau-Jonard C, Dewailly D. Anti-Mullerian hormone and polycystic ovary syndrome. Gynécol Obstét Fertil. 2011;39:514–7. CrossRef
- Kallio S, Aittomäki K, Piltonen T, Veijola R, Liakka A, Vaskivuo TE, et al. Anti-Mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Hum Reprod. 2012;27(3):854–60. CrossRef
- Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, et al. Anti-Müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009;94:786–92. CrossRef
- Smeenk JMJ, Sweep FCGJ, Zielhuis GA, Kremer JAM, Thomas CMG, Braat DDM. Anti mullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intra-cytoplasmic sperm injection. Fertil Steril. 2007;87:223–6. CrossRef
- Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy. Hum Reprod. 2007;22:2414–21. CrossRef
- Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol. 2010;150:166–70. CrossRef
- Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo quality. Hum Reprod. 2006;21:159–63. CrossRef
- Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum anti müllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323–9. CrossRef
- Blazar AS, Lambert-Messerlian G, Hackett R, Krotz S, Carson SA, Robins JC. Use of in-cycle antimüllerian hormone levels to predict cycle outcome. Am J Obstet Gynecol. 2011;205(3):223.e1-5. CrossRef
- Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S. Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet. 2011;284(5):1295–301. CrossRef
- Wang JG, Douglas NC, Nakhuda GS, Choi JM, Park SJ, Thornton MH, et al. The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age. Reprod BioMed Online. 2010;21(6):757–61. CrossRef
- Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF
Journal of Assisted Reproduction and Genetics
Volume 31, Issue 4 , pp 493-498
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Ovarian reserve
- Oocyte quality
- Industry Sectors
- Author Affiliations
- 1. Department of Obstetrics and Gynecology, University of Montreal, Montreal, QC, H3C 3J7, Canada
- 2. Clinique OVO, 8000 Bld. Décarie, Suite 600, Montréal, QC, H4P 2S4, Canada